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The dissolution profile for solid pharmaceutical forms containing chloramphenicol 250 mg available in Brazil was 
determined using a method from the American Pharmacopoeia (United States Pharmacopoeia, 2004) and then 
compared.  Two different methods of dissolution profile comparison were used: ANOVA, and an independent model. 
Differences between the formulations were reflected in the dissolution profiles.  The presence of metastable 
polymorphs or amorphous forms of chloramphenicol palmitate might be responsible for variations in the 
concentration of the drug observed within formulations. 
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INTRODUCTION 
 
Chloramphenicol is a large spectrum antibiotic 
with antimicrobial activity. Its mechanism of 
action is based on the inhibition of protein 
synthesis; however, the resistance of gram-positive 
and gram-negative microorganisms in vivo is a 
clinical problem of increasing importance 
(Kapusnik-Uner et al., 1996). Chloramphenicol is 
available for oral administration as 
chloramphenicol palmitate - a prodrug of 
chloramphenicol - developed with the objective of 
a more pleasent flavored derivative.  
Chloramphenicol palmitate is quickly and almost 
completely hydrolyzed by intestinal esterase, 
being distributed widely throughout corporal 
liquids and quickly achieving therapeutic levels 
(Singhal and  Curatolo, 2004). Therapy with 
chloramphenicol should be limited to infections 
where the benefit of the drug exceeds the risk of 
potential toxicity (Kapusnik-Uner et al., 1996). 
The absorption of drugs from solid pharmaceutical 
forms after oral administration depends, among 
other factors, on the liberation of the drug from the 
pharmaceutical form, its dissolution or solubility 
in physiological conditions, and its permeability 
through the gastrointestinal tract. Due to the 
critical nature of the two initial stages, dissolution 
tests in vitro can be relevant to predict the 
performance of the drug in vivo. Based on these 
considerations, dissolution tests are largely used to 
assure the quality of the pharmaceutical product.  
Methods for dissolution profile comparisons are 
suggested by SUPAC-IR (US, 1997). 
Due to economical reasons, the use of generic 
medicines has been given much incentive by 
health authorities throughout the world.  In Brazil, 
politics directed towards generic medicine was 
introduced in 1999 as an attempt to change the 
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national market.  However, this can be problematic 
if the quality control and/or bioequivalence is not 
reached (Meredith, 1996). 
The objective of this study was to the evaluate of 
the liberation in vitro (dissolution) of solid 
pharmaceutical forms containing chloramphenicol 
commercialized in Brazil. 
 
 
MATERIAL AND METHODS 
 
Pharmaceutical Forms 
Two different brands containing 250 mg of 
chloramphenicol palmitate in the form of film-
coated tablets (A, B), three different brands of 250 
mg of chloramphenicol palmitate in the form of 
sugar coated tablets (C, D, E) and three different 
brands containing 250 mg of chloramphenicol 
palmitate in the form of capsules (F, G and H) 
were tested. 
Procedures 
Studies were performed using Hanson Research 
Corp. model SR-6 equipment. Samples were 
submitted to the dissolution test as is described by 
the American Pharmacopoeia (United States 
Pharmacopoeia, 2004) for chloramphenicol 
capsules (Table 1). Dissolution profiles were 
obtained under the same conditions. Aliquots     
(10 mL) were removed in 1, 5, 10, 20, 40, and 60 
minutes, and analyzed espectrophotometrically in 
278 nm using a spectrophotometer Shimadzu 
model 1401. Aliquots from the dissolution 
medium without the drug (the same volume and 
the same temperature) were immediately added to 
the dissolution medium in order to maintain a 
constant volume during the test. Dissolution 
profiles were determinated by the USP XXVII 




Table 1 - Conditions used for the dissolution test described by USP XXVII (2004) for chloramphenicol 
capsules. 
Agitation System Apparatus 1 (basquet) 
Stirring rate 100 rpm 
Dissolution medium HCl 0.01 N 
Medium volume 900 mL 
Detection (method) Spectrophotometer UV  (278 nm) 




Comparison among dissolution profiles is 
recommended by the F.D.A (US, 1997). Two 
methods for dissolution profile comparisons were 
used: ANOVA and an independent comparison 
model. The parameter of dissolution efficiency 
(DE) was calculated using the dissolved 
percentage curves of the drug versus time, using 
the reason between the area above the curve 
(ASC) and the total area of the graph (surface), 
and expressed in percentage (Khan and  Rodhes, 
1975). The resulting DE values were submitted to 
statistical analysis using analysis variance 
(ANOVA) in order to detect the existence of 
significant differences between the respective lots.  
Following this procedure, an independent 
investigation model - Tukey test and the test of the 
minimal significant difference (MSD), was 
applied, dominating the multiple comparison tests. 
After the application of ANOVA, was possible to 
determine which products were considered similar 
(Bolton, 1990; Vieira, 1980). 
RESULTS AND DISCUSSION 
 
Sample quantification was based on a previously 
constructed calibration curve and submitted to a 
linear regression analysis.  Linear relations were 
obtained with the concentration interval of 5-30 
µg.mL-1 (r = 0.999504), according to the equation 
Abs = -0.00683428 + 0.029437 x C (C = µg.mL-1). 
Nowadays, the study of dissolution in vitro is 
considered a fundamental requirement in the 
pharmaceutical industry in order to assure the 
quality of solid pharmaceutical forms for oral use, 
guarantee the quality from lot to lot, orientate the 
development of new formulations and secure the 
uniformity quality and performance of the drug 
even after modifications. On a parallel basis, this 
allows formulation optimization in the 
development phase and, in the same way, it allows 
stability studies, manufacturing process 
monitoring, and the establishment of in vivo/in 
vitro correlations (Adams et al., 2001; Dressman et 
al., 1998; Skoug et al., 1996). 
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The dissolution test, according to the American 
Pharmacopoeia (United States Pharmacopoeia, 
2004), should obey the following criteria: in the 
first stage (S1), six tablets are tested, in such case 
that all are acceptable to the lot seeing that all 
tablets are within tolerance limits presented in the 
monograph (Q+5%). If the results are not in 
accordance with S1 , it is necessary to test six more 
tablets (S2). The tablet lot will be accepted if the 
average of the 12 tablets is greater or equal to Q, 
and there are no units inferior to (Q-15%). If the 
lot is rejected, test twelve more tablets (S3) is 
needed, and if the average of all 24 tablets is 
greater or equal to Q and, if no more than 2 tablets 
present inferior results to (Q-15%), the lot is 
supposed to be a acceptable. 
In the dissolution test for chloramphenicol tablets 
described in the American Pharmacopoeia (United 
States Pharmacopoeia, 2004), no less than 80% 
(Q+5%) should be dissolved in 30 minutes. The 
evaluated products D, G and H evaluated did not 
fulfill the specifications in the first stage, seeing 
that after 30 minutes of testing the dissolution of 
both was inferior to 80% of the quantity declared 
on the label. Product F fulfilled the specifications 
only in the second stage, S2    (Table 2). 
 
Table 2 - Percentage values of dissolved chloramphenicol shown in mean (M), standard deviation (SD) 
and respective variation coefficients (VC), obtained for products F, G and H on the dissolution test 
specified by United States Pharmacopoeia (2004). 
 % Dissolved 
F G H Vessels 
S1 S2   
1 82.83 93.07 39.39 2.05 
2 84.66 89.86 31.75 1.93 
3 82.06 76.10 38.78 1.95 
4 77.94 79.01 65.07 1.81 
5 92.77 84.82 69.35 2.09 
6 71.21 83.75 68.74 3.15 
M 83.17 52.18 2.16 
S.D. 6.60 17.30 0.49 
V.C. (%) 7.94 33.15 22.84 
 
 
Although this dissolution test was praised by 
various pharmacopoeias it did not permit an 
evaluation of the form in which the drug was 
released during the test, keeping in mind that only 
one collection was performed at the end of a 
previously established time.  In contrast, the use of 
dissolution profile, where various aliquots were 
collected and quantified during the test, made the 
construction of curves of “drug percentage versus 
time” possible. These curves allowed to achieve a 
series of parameters of useful dissolution kinetics 
in comparative studies of solid pharmaceutical 
form performances in vitro of (Ferraz, 1997). In 
this way, the evaluation of the dissolution profile 
could be auxiliary to the identification of 
formulations that presented potential risk in 
relation to the drug bioavailability (Shah et al., 
1995). Furthermore, it is apart from being a useful 
tool in the development of formulations where it is 
possible to select those which present better 
performance in relation to the drug liberation 
(Abdou, 1995). 
Evaluating the dissolved percentage curves versus 
time (Fig. 1), it could be observed that the 
analyzed products presented very distinct 
dissolution profiles, showing that the formulations 
were not homogeneous in relation to the in vitro 
drug liberation. 
The comparison of dissolution profiles using the 
independent comparison method, where the 
dissolution efficiency values (DE) were submitted 
to statistical treatment (Table 3a,b and Table 4), 
allowed for the observation of formulations A, B, 
C, D, E, F, G and H, for parameters of the 
described level (P = 1.95 E-23) and the value of F 
calculated at a level of significance of 5% (F = 
101.6), between themselves on average were not 
equal and homogeneous. 
The variance analysis allowed the following 
establishment: if the average populations were, or 
were not statistically equal. However, this type of 
analysis did not allow to detect if the averages 
were statistically different from the rest.  
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Figure 1 - Dissolution profile of chloramphenicol palmitate obtained from products A, B, C, D, E, 
F, G and H, for each time interval, in HCl 0.01 N environment. aEach data point 
represents the mean of 12 units. 
 
 
Table 3a - Individual values, average (M), Standard Deviation (SD) and Variation coefficient (VC) of 
Dissolution Efficiency (ED) for products A, B, C and D. 
Dissolution Efficiency, % Vessels 
A B C D 
1 87 43 81 0 
2 87 75 81 0 
3 81 74 93 2 
4 72 78 74 0 
5 61 53 76 1 
6 73 60 80 0 
M 76.83 63.83 80.83 0.5 
S.D. 10.13 14.11 6.62 0.84 
V.C. (%) 13.18 22.10 8.18 167.33 
 
 
Table 3b - Individual values, average (M), Standard Deviation (SD) and Variation coefficient (VC) of 
Dissolution Efficiency (ED) for products E, F, G and H. 
Dissolution Efficiency, % Vessels 
E F G H 
1 67 74 29 2 
2 72 74 24 2 
3 71 72 59 2 
4 64 74 42 2 
5 64 75 40 2 
6 65 69 37 2 
M 67.17 73.00 38.50 2.00 
S.D. 3.54 2.19 12.14 0.00 
V.C. (%) 5.28 3.00 31.55 0.00 
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Table 4 - Variance Analysis (ANOVA) of dissolution efficiency (DE) values for pharmaceutical products 
A, B, C, D, E, F, G and H. 
Variation source Liberty degrees Square sum Medium square F
a 
Between treatments 45428.3 7 6498.7 101.6 
Within treatments 2554.3 40 63.9  
Total 47982.7 47   
aSignificant for P > 0.05; Fcritical = 7,34. 
 
 
The Tukey test permit to the establishment of a 
minimal significant difference (MSD), which was, 
a difference of sample averages which should be 
understood as being statistically significant, on a 
determined level. According to the Tukey test, two 
averages were statistically different whenever the 
value of absolute difference between them was 
equal to or superior to the minimum significant 
difference (MSD) value (Vieira, 1980). With the 
application of the Tukey test it was possible to 
observe that, with a level of significance of 5%, 
the average of products D and H were are equal 
and significantly smaller than the average found 
for the other products (Table 5 and Fig. 2). 
Solid drugs may exist as crystalline substances or 
amorphous particles without identifiable structure. 
The amorphous or crystalline character substance 
can affect the stability and activity of the drug 
within the formulation. The amorphous form often 
presents greater solubility, dissolution velocity and 
bioavailability than the crystalline structure, being 
that, in the amorphous state, the necessary energy 
for molecule separation is less than that of the 
crystalline form. 
On the other hand, crystalline forms are more 
stable than amorphous forms (Ansel, 2000; 
Shargel, 1999; Grant, 2000). Crystalline 
substances can still exist in one or more forms. 
Common crystalline forms found in drugs are 
called polymorphous or solvates (Vippagunta et 
al., 2001). Solvates - also known as 
pseudopolymorphos - are crystalline forms that 
contain solvent molecules of a crystal nature. 
When the solvent is water, they are known as 
hydrates (Jozwiakowski, 2000; Carstensen, 2001). 
Polymorphs are different crystalline forms of the 
same pure substance, and possess the same 
chemical composition, but are different as to the 
internal structure of the crystal which is present in 
different conformations and/or arrangements and, 
as a result of this difference, the polymorphs 
present different physical-chemical properties 
(Grant, 1999; Shargel, 1999; Jozwiakowski, 2000; 
Vippagunta et al., 2001). The occurrence of 
polymorphs is very common, and it is estimated 
that one third of organic compounds present 
polymorphism. 
Polymorphs can present differences considering 
their properties (Grant, 1999): in arrangement 
(refraction index, conductivity, hygroscopy); 
thermodynamics (melting point and sublimation, 
internal energy, enthalpy, entropy, solubility, etc.); 
spectroscopy (electronic transition, rotational 
transition, nuclear spin transition); kinetics 
(dissolution velocity, solid state reactions, 
stability); surface (superficial free energy, 
superficial tension, form); and mechanics 
(hardness, compatibility, compressivness, flow, 
etc).  
 
Table 5 - Comparison of product dissolution profiles, using the independent model values of dissolution 
efficiency (DE), using the Tukey test and the minimum significant difference method (MSD = 14.75).  
Brands Homogeneous group MSD/Tukey's Test 
A B, C, E and F 
B A, E and F 
C A, E and F 
D H 
E A, B, C and F 
F A, B, C and E 
G G 
H D 
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Figure 2 - Statistical comparison of the dissolution efficiency values (DE) for products A, B, C, 




Concerning the existence of polymorphs, the most 
stable form generally presents lower solubility and 
consequently, the form which presents greater 
solubility is less stable, also referred to as 
metastable (Carstensen, 2001). For pharmaceutical 
products, these property differences between 
polymorphs and amorphous and crystalline forms 
directly affect the solubility and dissolution of the 
drug within its formulation, consequently affecting 
as the bioavailability as well (Byrn et al., 1995). 
Three polymorphs of chloramphenicol palmitate 
have been described in literature: two crystalline 
forms - β  form (Form A) is the most stable and 
bio-inactive; the α form (Form B) is one of the 
metastable and bioactive, and amorphous forms.  
In the solid state, there is a transition from α form 
(Form B) to β form (Form A), being that this 
process is irreversible. These crystalline forms 
differ in their physical-chemical properties 
(Banerjee et al., 1971; Miyamoto et al., 1973). 
Aguiar et al. (1967) demonstrated that the 
absorption of the α form (Form B) of 
chloramphenicol palmitate was significantly 
higher than the absorption of the α form (Form B) 
in humans. Serum levels were linearly 
proportional for the percentage of B form in 
mixtures containing both forms (A/B). 
Anderson (1966) investigated thirteen preparations 
of oral administration containing chloramphenicol 
palmitate, where five of them predominantly 
presented the polymorph A. Aguiar and  Zelmer 
(1969) demonstrated that the hydrolysis in vitro of 
the prodrug - chloramphenicol palmitate - of 
pancreatine was polymorph dependent, with 
significant hydrolysis of the α form (Form B) and 
little hydrolysis in the β form (Form A). This 
difference in the solubility probably results in a 
difference in the hydrolysis rates and is 
responsible for the oral absorption differences. 
Borka and  Bache-Hansen (1968) showed that, 
through spectroscopy of IV, the H bond of the OH 
group is stronger in the β form (Form A) than in 
the α form (Form B), and the degree of rotation of 
this group is a determining factor in the solvation 
and/or hydrolysis of chloramphenicol palmitate.  
Borka (1970), using differential thermal analysis 
and spectroscopy IV, identified the different 
polymorphs of chloramphenicol palmitate and 
studied its transition phase diagram. α form (Form 
B) - although metastable - has a superior stability, 
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which together with its low solubility in water, 
guarantees stable formulations in solid forms or in 
suspension. Aguiar and  Zelmer (1969), continuing 
their work, related the thermal behavior of 
chloramphenicol palmitate with the absorption 
data in vivo and concluded, through 
thermodynamic parameters, that when the free 
energy difference between polymorphs is high, 
alterations of absorption profiles can occur, 
however, if the free energy difference is low, there 
are no significant differences in absorption.  
Banerjee et al. (1971) studied the absorption in 
vivo of the polymorph A and the amorphous form 
of suspensions of chloramphenicol palmitate and 
concluded that the absorption of the amorphous 
form is “significantly superior”. 
During the development of pharmaceutical 
formulations, the main objective is to formulate 
physically and chemically stable products as long 
as they present bioavailiblability. For drugs that 
present polymorphism, identification of the most 
thermodynamically stable polymorphs is 
recommended - less energy -, to assure the 
reproducibility in the bioavailability of the product 
during storage. There are situations where the 
development of amorphous crystalline metastable 
forms is justifiable due to therapeutic benefits.  
Such situations include those in which the highest 
dissolution and concentration are desired in order 
to obtain quick absorption and efficiency.  If there 
are no justifiable reasons, the intentional 
development of a metastable form can generate 
risks for the patient. On the other hand, the 
existence of multiple crystalline modifications not 
recognized in a formulation can result in 
significant variations in dosage and compromise 





Including as a reference, the literature data as well 
as data obtained experimentally, it could be 
concluded that significant differences existed in 
the liberation standards in vitro of 
chloramphenicol palmitate in solid pharmaceutical 
forms commercialized in Brazil; among the 
analyzed products, G and H were not approved by 
the criteria proposed by the American 
Pharmacopoeia (2004) and presented unacceptable 
performance in the dissolution test. Dissolution 
profiles presented by these products were equal on 
average, and significantly less than the average 
found for the other products involved. 
During the development of pharmaceutical 
formulations - innovator or generic - was expected 
that chemically and physically stable products 
would be formulated, in such a way that they were 
bioavailable. For drugs that present polymorphism, 
identification of the polymorph most 
thermodynamically stable of the drug is 
recommended - less energy -, to assure the 
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O perfil de dissolução de formas farmacêuticas 
sólidas contendo palmitato de cloranfenicol 250 
mg disponíveis no Brasil foi determinada pelo 
método da Farmacopéia Americana (United States 
Pharmacopeia, 2004) e comparado. Duas 
categorias de métodos para comparação dos perfis 
de dissolução foram utilizadas: ANOVA e modelo 
independente. Diferenças entre as formulações 
foram refletidas nos perfis de dissolução. A 
presença de polimorfos metaestáveis ou formas 
amorfas de palmitato de cloranfenicol pode ser 
responsável pelas variações na concentração do 
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